Tag: big pharma

Medicine Has Been Fully Militarized

Iam thinking of a certain industry. See if you can guess what it is.

This industry is huge, constituting a large portion of the nation’s GDP. Millions of people earn their living through it, directly or indirectly. The people at the top of this industry (who operate mostly behind the scenes, of course) are among the super-rich. This industry’s corporations lobby the nation’s government relentlessly, to the tune of billions of dollars per year, both to secure lucrative contracts and to influence national policy in their favor. This investment pays off richly, sometimes reaching trillions of dollars.

The corporations supplying this industry with its materiel conduct advanced, highly technical research that is far beyond the understanding of the average citizen. The citizens fund this research, however, through tax dollars. Unbeknownst to them, many of the profits gained from the products developed using tax dollars are kept by the corporations’ executives and investors.

This industry addresses fundamental, life-or-death issues facing the nation. As such, it relentlessly promotes itself as a global force for good, claiming to protect and save countless lives. However, it kills a lot of people too, and the balance is not always a favorable one.

The operational side of this industry is emphatically top-down in its structure and function. Those who work at the ground level must undergo rigorous training that standardizes their attitudes and behavior. They must follow strict codes of practice, and they are subject to harsh professional discipline if they deviate from accepted policies and procedures, or even if they publicly question them. 

Finally, these ground-level personnel are handled in a peculiar manner. Publicly, they are frequently lauded as heroes, particularly under declared periods of crisis. Privately, they are kept completely in the dark regarding high-level industry decisions, and they are often lied to outright by those at higher levels of command. The “grunts” even significantly forfeit some fundamental civil liberties for the privilege of working in the industry.

What industry am I describing?

If you answered, “the military,” of course you would be correct. However, if you answered “the medical industry,” you would be every bit as right.

Keep reading

Several Common Drugs Are Linked to Dementia

It is well-known that dementia is often a result of aging. However, sometimes it can be caused by medications.

Drug-induced dementia, the late neurologist and neurosurgeon K.K. Jain wrote, is a type of reversible dementia different from common neurodegenerative disorders.

Several drugs increase the risks of dementia, the most prominent being anticholinergic drugs, anti-epileptics, oncology drugs, and sedative-hypnotic drugs. These are all common prescriptions for older people.

In recent years, antidepressants have also been linked with dementia risks.

Psychiatrist Dr. Peter Breggin, who has published several books on psychopharmacology, told The Epoch Times that most drugs on the market have some degree of neurotoxicity, which can lead to cognitive and neurological side effects.

Not everyone will be affected by a drug’s neurotoxic effects, though older people and those with brain deficits are more vulnerable.

With illnesses that surface in old age and the pills prescribed to treat each symptom, older people also tend to be the most likely cohort to be prescribed drugs that damage their cognition.

Keep reading

More than 50% of CDC employees end up working for Pharma

A study conducted by researchers at the University of Southern California (USC) and Harvard University and published in the journal Health Affairs found that 54 percent of the staff members, who were employed at the U.S. Centers for Disease Control and Prevention (CDC) and left the federal health agency during 2004-2020, went on to work for the pharmaceutical industry.

According to the study:

Exiting staff went to not only biopharmaceutical and device manufacturers, but also health insurers, information and communication technology firms, real estate firms with medical property portfolios, and consulting firms.

The study researchers, Genevieve Kanter, PhD and Daniel Carpenter, PhD, stated that the “high rates of exit” to pharmaceutical companies suggests that CDC employees, as well as employees of other operating divisions of the U.S. Department of Health & Human Services (DHHS), are highly valued and make them attractive hires for pharmaceutical companies, and that this value could “derive from policy expertise, extended professional networks, or prestige.”

But Drs. Kanter and Carpenter also pointed out that there is concern that some of the value of people who used to work for the CDC may come from the perceived “potential influence” that these hires can “exert on former colleagues post-departure, or from favorable actions taken before departure, that could compromise agency decision making.

Keep reading

Drugmakers Hid Suicides, Manipulated Data to Falsely Show Safety in Antidepressant Drug Trials

Every now and then, a highly profitable pharmaceutical will come along that everyone also knows is quite dangerous.

Remarkably, rather than this stopping the product, it will often be pushed to market and the profits it generates will be used to ensure any objections to its safety get ignored and blown to the wayside.

One of my goals in writing has hence been to review the scandalous history of some of the most dangerous pharmaceuticals on the market.

This was done both to help those being harmed by them (e.g., consider the story of statins and the story of nonsteroidal anti-inflammatory drugs, or NSAIDs) and to illustrate that the horrendous malfeasance we’ve observed from the U.S. Food and Drug Administration (FDA) throughout COVID-19 has been its standard operating procedure.

For example, I recently covered the story of Merck’s Vioxx, an unsafe and unneeded painkiller that was kept on the market until outside investigators proved it was causing heart attacks and strokes (estimated to have killed 120,000 people by the time Vioxx was withdrawn), something Merck was fully aware of from the start.

Keep reading

Paxlovid Does Not Reduce Risk Of Long COVID, Potentially Linked To Rebound Symptoms: Study

Paxlovid, an antiviral medication prescribed to treat symptoms associated with COVID-19, does not reduce the risk of developing long COVID in vaccinated people recovering at home.

The report comes from a new study published in the Journal of Medical Virology on Thursday. Conducted by a team of researchers from the University of California–San Francisco, the study also found that more people are experiencing rebounds of their COVID symptoms after taking Paxlovid (nirmatrelvir-ritonavir) than previously reported.

Paxlovid is the first antiviral pill approved by the U.S. Food and Drug Administration (FDA) to treat mild and moderate COVID-19 in adults. It is typically prescribed to those at high risk of having the virus progress to a severe illness, including hospitalization or death. The medication has also been authorized for use in children 12 and older who are at risk of severe outcomes from COVID-19.

According to manufacturer Pfizer, initial trials of Paxlovid showed it reduced hospitalizations and death in unvaccinated COVID patients by 86 percent to 89 percent. A real-world study conducted by the U.S. Centers for Disease Control and Prevention (CDC) showed that adults who took Paxlovid within the first five days of a COVID-19 diagnosis had a 51 percent lower hospitalization rate within 30 days than those who did not take the medication. More recent studies have indicated lower efficacy rates, with patients having about 37 percent reduced hospitalization and death risk.

However, no study has pointed to whether the drug helps protect people from getting long COVID, noted authors of the UC San Francisco study.

Keep reading

Landmark Case Means Americans Can Now Sue Big Pharma for Vaccine Injuries

Up until now, the drug companies have been shielded from liability for all the COVID vaccine injuries and deaths that they have caused. They’re protected by something called the PREP Act, which stands for Public Readiness and Emergency Preparedness. A judge in a landmark Michigan case, however, has now ruled that the PREP Act does not shield the Big Pharma companies from liability if their medicines are contaminated.

That’s it. The floodgates are finally open. If you were hurt by a COVID shot or if one of your loved ones died from it, you can now sue the Big Pharma companies.

The Michigan case was brought by Dan Nowacki, an elderly man who was hospitalized with COVID. Mr. Nowacki was treated with Remdesivir, which is a COVID treatment drug made by pharmaceutical company Gilead. Remdesivir is a relatively new treatment, so it’s shielded under the PREP Act.

Mr. Nowacki was treated with Remdesivir intravenously. His attorneys just proved in court that at least two of the vials that Mr. Nowacki was administered were contaminated with shards of glass. It caused him to have two catastrophic strokes in the hospital. He’s now permanently bedridden. About 55,000 vials of Remdesivir were recalled in November of 2021 due to glass contamination.

The judge ruled that the pharmaceutical companies’ liability shielding does not protect them in the case of contamination. If the Big Pharma companies are being protected from being sued, then they still have to meet basic safety standards. They can’t just inject their medicines into people if they know that those medicines are contaminated with shards of glass, arsenic, or… just to name one possible contaminant off the top of our head… cancer-causing monkey viruses.

Keep reading

OxyContin’s Reformulation Linked to Rising Suicides by Children

In 2010, Purdue Pharma replaced the original version of OxyContin, an extended-release oxycodone pill, with a reformulated product that was much harder to crush for snorting or injection. The idea was to deter nonmedical use, and the hope was that the reformulation would reduce addiction and opioid-related deaths. That is not how things worked out.

The reformulation of OxyContin was instead associated with an increase in deaths involving illicit opioids and, ultimately, an overall increase in fatal drug overdoses. Researchers identified that pattern by looking at the relationship between pre-2010 rates of OxyContin misuse, as measured by surveys, and subsequent overdose trends. They found that death rates rose fastest in states where reformulation would have had the biggest impact. A new study by RAND Corporation senior economist David Powell extends those findings by showing that the reformulation of OxyContin also was associated with rising suicides among children and teenagers.

The root cause of such perverse effects was the substitution that occurred after the old version of OxyContin was retired. Nonmedical users turned to black-market alternatives that were more dangerous because their potency was highly variable and unpredictable—a hazard that was compounded by the emergence of illicit fentanyl as a heroin booster and substitute. The fallout from the reformulation of OxyContin is one example of a broader tendency: Interventions aimed at reducing the harm caused by substance abuse frequently have the opposite effect.

From 1988 to 2010, Powell notes in the journal Demography, the suicide rate among 10-to-17-year-olds fell by 36 percent. That drop was “followed by eight consecutive years of increases—resulting in an 83% increase in child suicide rates.” Based on interstate differences in nonmedical use of OxyContin prior to 2010, Powell estimates that “the reformulation of OxyContin can explain 49% of the rise in child suicides.”

Since “the evidence suggests that children’s illicit opioid use did not increase,” Powell says, it looks like “the illicit opioid crisis engendered higher suicide propensities by increasing suicidal risk factors for children,” such as child neglect and “alter[ed] household living arrangements.” He notes a prior study that found “states more
affected by reformulation experienced faster growth in rates of child physical abuse
and neglect starting in 2011.” And he suggests the suicide rate may also have been boosted by “parental death and incarceration” associated with the shift from legally produced pharmaceuticals to illicit drugs.

Keep reading

A Threat To Humanity: WHO, Gates, and Big Pharma Make Pandemic Treaty

Intended to form part of international law, preparations for the creation of a World Health Organisation (“WHO”) Pandemic Treaty or Pandemic Accord began in 2001.

Far from strengthening the prevention of, preparedness for, and response to future pandemics as the latest draft of the text claims, its implementation could severely undermine democracy by limiting the ability of national parliaments to make crucial healthcare decisions in the best interests of their citizens.

Aided by proposed amendments to the International Health Regulations of 2005, the Treaty threatens to transform the WHO into a global health dictatorship.

Keep reading

Pfizer ‘Knowingly Distributed’ Adulterated Drugs to Children: Lawsuit

Pfizer and one of its partners distributed a medication to children despite having knowledge that the drug was adulterated, according to legal action unsealed on Nov. 20.

Pfizer and Tris Pharma distributed Quillivant XR, a drug for children aimed at treating attention-deficit/hyperactivity disorder (ADHD), even though the companies knew the drug did not meet federal standards, the lawsuit from Texas Attorney General Ken Paxton says.

The U.S. Food and Drug Administration (FDA) approved Quillivant in 2012 but soon after its approval, the drug failed quality control tests, according to the suit.

Instead of investigating the root cause, as required by federal rules, Tris repeatedly changed testing methods allegedly to try to generate positive results, Mr. Paxton’s probe found. Tris was “under financial pressure” to “rapidly increase production” and did ramp up production but “without adequate controls,” the suit states.

Quillivant comes in powder form and is reconstituted by pharmacists with water.

The medication is a schedule II controlled dangerous substance, and suppliers are required by the FDA to ensure display of a black box warning about abuse and dependence, and the potential side effects which include nausea, vomiting, and insomnia. It was developed by Nextwave Pharmaceuticals, and was acquired by Pfizer in May 2012.

Keep reading